BioSpace News Archive

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the first quarter 2023 after the U.S. market close on Wednesday, May 10th, 2023.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of the market.

Arcutis Biotherapeutics, Inc., an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.

PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.

With an increasing number of scientists raising their concerns over research on exotic viruses worldwide and the debate on SARS-CoV-2’s origin still raging, AIDS Healthcare Foundation (AHF) urges all countries to promote international transparency and strict oversight on work with highly-contagious, pandemic-capable viruses.

Alpenglow Biosciences today announced a collaboration with Mayo Clinic to integrate Alpenglow’s 3D spatial biology platform to accelerate drug development and advance clinical diagnostics.

IntraBio Inc announced it completed and closed its $15 Million Series C funding round on April 5, 2023.

Outset Medical, Inc. is presenting five new abstracts providing promising insights on the clinical and financial benefits of home hemodialysis, gender biases toward female nephrologists and other pertinent topics related to kidney disease.

Gestalt Diagnostics Inc. and ARUP Laboratories announced that ARUP has selected Gestalt’s award-winning PathFlow® digital platform as the solution to support its comprehensive vision for digital pathology.